Paula Azevedo1, Camila C Aquino2,3, Alfonso Fasano1,4,5. 1. Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Division of Neurology University of Toronto Toronto Ontario Canada. 2. Department of Clinical Neurosciences University of Calgary Calgary Alberta Canada. 3. Hotchkiss Brain Institute, University of Calgary Calgary Alberta Canada. 4. Krembil Brain Institute Toronto Ontario Canada. 5. CenteR for Advancing Neurotechnological Innovation to Application (CRANIA) Toronto Ontario Canada.
Abstract
BACKGROUND: Deep Brain Stimulation (DBS) is an increasingly popular therapy for Parkinson's Disease (PD). Despite the experience gained over time with DBS of either the subthalamus or the globus pallidus pars interna, there is still no consensus regarding the age limit for DBS indication. OBJECTIVES: This narrative review of the literature discusses the issues of age and DBS, emphasizing the critical need for good quality evidence to support the surgical management of elderly patients with PD. METHODS: We searched PubMed using the terms Parkinson's Disease; Parkinson's Disease therapy; deep brain stimulation; antiparkinsonian agents therapeutic use; age factors; aged; aged, 80 and over; middle aged; treatment outcome; and risk assessments. RESULTS: We identified several limitations of the available evidence, such as under-representation of older patients in DBS studies, small sample sizes in studies with older participants, heterogeneity of outcomes, and conflicting results. CONCLUSIONS: Despite preliminary suggestions that age might affect the outcomes of DBS, the evidence to support the hypothesis of age as an independent predictor of DBS outcomes is limited and results are controversial. Ultimately, finding an age-independent biomarker predicting DBS outcome is the final goal to expand this powerful treatment to all patients age in an effective and safe manner.
BACKGROUND: Deep Brain Stimulation (DBS) is an increasingly popular therapy for Parkinson's Disease (PD). Despite the experience gained over time with DBS of either the subthalamus or the globus pallidus pars interna, there is still no consensus regarding the age limit for DBS indication. OBJECTIVES: This narrative review of the literature discusses the issues of age and DBS, emphasizing the critical need for good quality evidence to support the surgical management of elderly patients with PD. METHODS: We searched PubMed using the terms Parkinson's Disease; Parkinson's Disease therapy; deep brain stimulation; antiparkinsonian agents therapeutic use; age factors; aged; aged, 80 and over; middle aged; treatment outcome; and risk assessments. RESULTS: We identified several limitations of the available evidence, such as under-representation of older patients in DBS studies, small sample sizes in studies with older participants, heterogeneity of outcomes, and conflicting results. CONCLUSIONS: Despite preliminary suggestions that age might affect the outcomes of DBS, the evidence to support the hypothesis of age as an independent predictor of DBS outcomes is limited and results are controversial. Ultimately, finding an age-independent biomarker predicting DBS outcome is the final goal to expand this powerful treatment to all patients age in an effective and safe manner.
Authors: Jeff M Bronstein; Michele Tagliati; Ron L Alterman; Andres M Lozano; Jens Volkmann; Alessandro Stefani; Fay B Horak; Michael S Okun; Kelly D Foote; Paul Krack; Rajesh Pahwa; Jaimie M Henderson; Marwan I Hariz; Roy A Bakay; Ali Rezai; William J Marks; Elena Moro; Jerrold L Vitek; Frances M Weaver; Robert E Gross; Mahlon R DeLong Journal: Arch Neurol Date: 2010-10-11
Authors: Vincent J J Odekerken; Judith A Boel; Ben A Schmand; Rob J de Haan; M Figee; Pepijn van den Munckhof; P Richard Schuurman; Rob M A de Bie Journal: Neurology Date: 2016-01-27 Impact factor: 9.910
Authors: Harriet M M Smeding; Johannes D Speelman; Hilde M Huizenga; P Richard Schuurman; Ben Schmand Journal: J Neurol Neurosurg Psychiatry Date: 2009-05-21 Impact factor: 10.154